Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner
Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 15. Characteristics Predictive of Disease Response or Survival: Group 4—Other Factors

Prognostic factor Studies indicating an association and quality Strength of association with tumor response Strength of association with survival
Bone marrow cellularity Frater, 2003109
(Quality = 1/5)
CP-IFN-r
BM cellularity 100% N =13 with decrease when responds to I  
Myelosuppression Sneed, 2003110
(Quality 5/6)
CP-IFN-r
Any myelosuppression >Grade 3:
Yes (N=76) MCR 62% CCR 45%
No (N=67) MCR 78% CCR 64%
   p=0.01

Any myelosuppression >Grade 3 for > 2wk duration:
Yes (N=50) MCR 58% CCR 36%
No (N=93) MCR 75% CCR 63%
   p=0.001
 
Persistent BCR-ABL in CD34+ cells after CCR with I Bhatia, et al., 200327
(Quality = 2/5)
CP & AP
100% (N=15) had persistent evidence of BCR-ABL by FISH or RT-PCR up to 61 months (range 1-61) after starting I  
Evidence of BCR-ABL in CCR Paschka, 200310
(Quality = 4/6)
CP, AP & BC
21/68 (31%) samples derived from pts in CCR by conventional cytogenetics have evidence of residual disease by HM-FISH

All (N=234) samples of CCR patients had evidence of BCR-ABL by RT-PCR
 
Abnormal cytogenetics in Ph- cells O'Dwyer, 200335
(Quality 2/5)
CP-IFN-r
Clones with abnormal cytogenetics could be identified in the Ph- cells of 7 patients in MCR; link to disease outcome not presented  

Abbreviations: AP = Accelerated Phase; BC = Blast crisis; CP = Chronic Phase; CCR = complete cytogenetic response; I = Imatinib; MCR = Major cytogenetic response, Ph- = Philadelphia chromosome negative; pt(s) = patient(s)

Return to Document

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care